Finnzymes. (2/1/10). "Press Release: To Valued Customers of Finnzymes".

	Region	Espoo
	Country	Finland
	Organisation	Finnzymes Oy
	Group	Thermo Fisher (Group)
	Organisation 2	Thermo Fisher Scientific Inc. (NYSE: TMO)
	Group	Thermo Fisher (Group)
	Index term	Finnzymes–Thermo Fisher: investment, 201002–201003 acquisition

To Valued Customers of Finnzymes,

We are pleased to inform you that Thermo Fisher Scientific has signed an agreement to acquire Finnzymes. Founded in 1986 and headquartered in Espoo, Finland, Finnzymes is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Our aim is to develop products that make the difference, products that deliver results not achievable otherwise. Finnzymes' core strength is its long experience and extensive know-how in PCR and qPCR technology. Our PCR product line includes all components required for PCR: DNA polymerases, PCR instruments and reaction vessels. Our PCR and qPCR products are thoroughly validated with all the major systems on the market. This acquisition will enable us to better support you and our other customers by offering leading technologies and a more complete portfolio in PCR and strengthening our support and distribution channels around the world.

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling its customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, the company has approximately 35,000 employees and serves over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Thermo Fisher Scientific is headquartered in Waltham, MA, USA.

Both companies share a strong commitment to innovation and advancing nucleic acid detection technologies in order to make the PCR [polymerase chain reaction] process faster, more accurate and more reliable. Finnzymes' leading enzyme portfolio and unique PCR instrument platform will strengthen Thermo Fisher's broad range of life science reagents and consumables and its specialty diagnostic products and services. The combination of the two portfolios brings together leading technologies for molecular biology and diagnostics.

Our company will be integrated primarily into Thermo Fisher Scientific's Analytical Technologies Segment, with some equipment and consumables product lines being added into the Laboratory Products and Services Segment. The transaction is expected to close during the first quarter of 2010. Until then, Finnzymes will continue to operate as a standalone company. There will be no immediate change in dayto- day operations as a result of today's announcement.

Earning the trust of our customers has been -and will continue to be- a top priority for Finnzymes. Rest assured that your needs will be paramount as we move forward to the next stage of the company's development. Customers can expect the same commitment to innovation and exceptional support they have come to rely on from Finnzymes and our global channel partners. As always, we are ready to assist 24 hours a day, every day of the year.

Finnzymes Customer Support:
* Website: www.finnzymes.com
* Phone: +358-9-2472-3010
* Email: fz@finnzymes.fi

Sincerely,
Pekka Mattila, CEO

Record changed: 2016-03-19

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Associations

Advertise

Finnzymes. (2/1/10). "Press Release: To Valued Customers of Finnzymes".

More documents for Thermo Fisher (Group)